Valuation: Verastem, Inc.

Market Cap 747M 669M 624M 566M 1.07B 71.42B 1.07B 7.49B 2.93B 36.86B 2.81B 2.74B 119B P/E 2026 *
-5.02x
P/E 2027 * -7.08x
Enterprise Value 789M 706M 658M 597M 1.13B 75.43B 1.13B 7.91B 3.1B 38.92B 2.96B 2.9B 125B EV / Sales 2026 *
6.8x
EV / Sales 2027 * 4.14x
Free-Float
98.91%
Yield 2026 *
-
Yield 2027 * -
10-07 B. Riley Adjusts Verastem Price Target to $19 From $16, Maintains Buy Rating MT
09-28 Verastem Oncology Announces Publication Of Two-Year Long-Term Results From Phase 2 RAMP 201 Study Evaluating AVMAPKI FAKZYNJA CO-PACK In Recurrent Low-Grade Serous Ovarian Cancer CI
09-18 Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says MT
09-17 Wolfe Research Initiates Verastem at Outperform MT
09-14 RTW Biotech NAV rises 15% as public investments drive returns AN
09-08 Verastem Oncology Unveils New Clinical Data Highlighting The Best-In-Class Potential Of VS-7375, An Oral KRAS G12D (ON/OFF) Inhibitor Across Pancreatic, Lung, And Colorectal Cancers CI
08-11 Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating MT
08-07 Verastem, Inc. Amends Note Purchase Agreement to Establish New Series of Senior Secured Revenue Notes Up to $75 Million CI
08-06 Verastem, Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06 Verastem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-28 Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer CI
07-22 Verastem Oncology Doses First Patient in Target-D 202 Phase 2 Registration-Directed Trial of Vs-7375 for Kras G12d-Mutated Advanced Non-Small Cell Lung Cancer CI
07-07 RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating MT
1 day-1.55%
1 week+3.12%
Current month+2.48%
1 month+12.70%
3 months+49.19%
6 months+55.37%
Current year+6.87%
1 week 7.65
Extreme 7.65
8.6
1 month 7.2
Extreme 7.195
8.64
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
10.82
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
39.6
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 2023-07-31
Director of Finance/CFO 39 2022-10-30
Chief Tech/Sci/R&D Officer - 2024-04-17
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 2023-07-31
Director/Board Member 69 2017-05-02
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Sell

Chief Financial Officer

-2,566 0.0042%
10/1/26 Sell

Chief Executive Officer

-44,121 0.0717%
9/21/26 Sell

Chief Financial Officer

-55 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%+3.12%-3.73%+7.84% 759M
+0.03%-5.67%+50.74%+76.76% 70.61B
+0.66%-9.75%+6.97%+52.62% 51.01B
+0.31%-0.14%+8.84%+32.99% 48.1B
+0.90%-1.46%+32.32%+32.69% 42.78B
+2.21%-6.61%+302.05%+701.45% 40.67B
-1.15%-3.11%+9.47%+98.83% 40.3B
+0.45%-1.20%+9.11%+43.54% 30.59B
-3.13%-12.00%+41.29%+3.77% 28.16B
-1.16%-1.84%-6.09%-11.99% 24.36B
Average -0.25%-2.22%+45.10%+103.85% 37.73B
Weighted average by Cap. +0.07%-2.96%+52.22%+118.61%

Financials

2026 *2027 *
Net sales 116M 104M 96.84M 87.84M 166M 11.09B 167M 1.16B 456M 5.72B 436M 426M 18.42B 180M 162M 151M 137M 258M 17.25B 259M 1.81B 708M 8.9B 678M 663M 28.64B
Net income -166M -149M -139M -126M -237M -15.88B -239M -1.67B -652M -8.2B -624M -610M -26.38B -158M -141M -132M -119M -225M -15.08B -227M -1.58B -619M -7.78B -592M -579M -25.03B
Net Debt 41.9M 37.51M 34.97M 31.72M 59.82M 4.01B 60.19M 420M 164M 2.07B 157M 154M 6.65B -
Projected Income Statement - Annual - Verastem, Inc.
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
26-10-12 US$8.250 -1.55% 3,582,256
26-10-09 US$8.380 +3.33% 2,970,338
26-10-08 US$8.110 -1.88% 3,051,551
26-10-07 US$8.265 +6.65% 3,928,558
26-10-06 US$7.750 -3.12% 2,513,883
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Verastem, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.250USD
Average target price
15.00USD
Spread / Average Target
+81.82%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Verastem, Inc.
  1. Stock Market
  2. Stocks
  3. VSTM Stock